Ignyta’s Story

Ignyta’s audacious goal is to eradicate residual disease in precisely defined patient populations by 2030.

Click through the yearly slides to read the story of Ignyta from our founding through today. And visit our offices in San Diego to see the Ignyta interactive timeline wall (also shown here) which includes our audacious future goals, all the way through 2030.

From our founding in 2011 as a molecular diagnostic company to our inexorable march towards achieving our bold vision for patients, this is Ignyta’s timeline – your story, our story…the story we’re writing every day.

The Ignyta Timeline Wall, at Ignyta's facility in San Diego, California

2011 – Ignyta is founded to catalyze precision medicine for the benefit of patients

The Ignyta Heatmap - The Image That Started Ignyta

From our earliest days, we have focused on becoming the best precision medicine company in the world, using trailblazing science to fuel exceptional patient benefit, employee engagement, and shareholder value.

This is the image that sparked the launch of Ignyta. It shows a heat map of DNA methylation signatures found in fibroblast-like synoviocyte (FLS) cell lines, showing that FLS from patients with rheumatoid arthritis (RA) seems dissimilar from patients with osteoarthritis (OA), a finding that could be used for potential diagnostic and therapeutic applications.

Ignyta was founded by Jonathan Lim and Gary Firestein to explore the use of DNA methylation as a potential novel diagnostic tool for autoimmune disease.

2012 – Ignyta’s foundational core values are set

The Ignyta 2012 Values Jam Whiteboard

From our earliest days, we have focused on becoming the best precision medicine company in the world, using trailblazing science to fuel exceptional patient benefit, employee engagement, and shareholder value.

On October 3, 2012, when the entire company could still fit comfortably in a small conference room, we conducted a “Values Jam” (original notes shown here) to define how we work to accomplish our goals. The resulting values (with the original values icons below) paint the picture of Ignyta’s unwavering commitment to patients and the values we abide by every day as we work tirelessly on their behalf. See the complete list and their explanations on the Ignyta Vision and Values page, and learn more about the people who live these values every day on our People, Culture, and Careers page.

The original Ignyta Values Icons from 2012
The original Ignyta Values icons.

2013 – Ignyta pursues an integrated Rx/Dx model

Ignyta Inc. article in 2013 issue of BioWorld Today

In May 2013, we added precision therapeutics (Rx) to our arsenal and became one of the only companies capable of end-to-end in-house identification, testing, and (eventually) treatment of molecularly driven cancers in certain hard-to-find populations.

In October 2013, we successfully in-licensed entrectinib – a Trk, ROS1, and ALK inhibitor from Nerviano Medical Sciences, and our Rx/Dx model was fully realized.

Today, Ignyta’s foundation remains a singular, unwavering focus on patients, enabled by an integrated Rx/Dx model that allows Ignyta to quickly locate and effectively target patients for whom Ignyta’s groundbreaking therapies can provide new hope.

2014 – Ignyta presents landmark Trk inhibitor response at ASCO and achieves CLIA certification

Pre-treatment and Cycle 1 CT scans of a 75-year-old female patient with Trk fusion metastatic colorectal cancer

To the left are the pre-treatment and Cycle 1 CT scans of a 75-year-old female patient with Trk fusion metastatic colorectal cancer refractory to multiple prior therapies, including FOLFOX, FOLFIRI/cetuximab, and irinotecan. Her partial response was the first-ever response in a patient with a Trk fusion cancer treated with a Trk inhibitor.

Ignyta's 2014 CLIA Certification

At ASCO 2014, Ignyta first presented evidence of Trk as a druggable target in oncology. In November of that year, Ignyta’s San Diego diagnostic laboratory passed the State of California survey for Clinical Laboratory Improvement Amendments (CLIA) certification, granting Ignyta permission to offer molecular diagnostic services to patients. This represented a milestone for Ignyta’s integrated Rx/Dx approach to serving cancer patients.

2015 – Ignyta puts entrectinib on the map at ASCO and launches STARTRK-2

CT scans of a 46 year old male patient with NTRK1 fusion non-small cell lung cancer (NSCLC), treated with entrectinib

At ASCO 2015, Ignyta presented Phase I clinical trial data for entrectinib, demonstrating that the drug candidate was well tolerated with no drug-related serious adverse events. A recommended Phase 2 dose was determined, and a 91% response rate in patients’ meeting expected Phase 2 eligibility criteria was observed. Ignyta initiated the STARTRK-2 pivotal Phase 2 clinical trial of entrectinib in September 2015.

Pictured here are the CT scans of a 46-year-old male patient (“Mr. Z”) with NTRK1 fusion non-small cell lung cancer (NSCLC) metastatic to the brain that was refractory to carboplatin/pemetrexed, pembrolizumab, docetaxel, and vinorelbine. Mr. Z’s health rapidly deteriorated, and he was admitted to hospice care.

Ignyta patient Mister Z with Chief Executive Officer Jonathan LimMr. Z was subsequently enrolled in Ignyta’s STARTRK clinical trial of entrectinib, and the results were dramatic. Visit the Ignyta Patient Stories page to read Mr. Z’s amazing story, and the stories of other patients Ignyta has had the honor to treat in our clinical trials.